Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Health Economics

- PMLiVE

The role of economic evaluation in US healthcare

Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking...

Mtech Access

Innovative Trials opens first US office

We are incredibly excited to announce the opening of our very first US office! This is an incredible milestone towards our mission to accelerate clinical development. Read the full press...

Innovative Trials

- PMLiVE

Innovative Trials opens first US office

The leading global patient recruitment organisation has opened its first international office in the Raleigh, North Carolina

Innovative Trials

- PMLiVE

Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)

Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed...

Avalere Health

Biogen Idec building

ICER says price of Biogen’s Aduhelm should be much lower

US cost-effectiveness watchdog’s analysis estimates current annual list price of $56,000 could be reduced to $3,000 to $8,400

- PMLiVE

ICER to review the role of health insurers in determining patient access to prescription drugs

Non-profit research institute will evaluate how health insurance policies may harm patient access to treatment

- PMLiVE

ICER extends evaluation of Biogen’s aducanumab after FDA delay

FDA delayed its decision on potential Alzheimer's therapy to 7 June

- PMLiVE

AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

Updated draft evidence report maintains the benefit is small with higher price tag

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

The most annoying ‘F’ word in healthcare

Why fail first policies are an ugly metaphor for larger issues

- PMLiVE

Aimmune wins over ICER for peanut allergy product

Analysts predict blockbuster status for first-in-class

- PMLiVE

How to pay for very high cost, curative drugs? ICER and NICE put their heads together

Three HTA bodies seek answers to future value models

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links